LXRX

Lexicon Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.82

Price (1 Year)

$2.55 $1.14

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %9.9 / %30
Non-compliant assets / Total market cap %26.5 / %30
Non-compliant revenue / Total income %14.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Website

Analysis (Turkish): LXRX Hissesi Caiz mi, Helal mi? Lexicon Pharmaceuticals, Inc. Katılım Analizi